Data Insights

Ligufalimab by Akeso for Myelodysplastic Syndrome: Likelihood of Approval

Ligufalimab is under clinical development by Akeso and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Ligufalimab in Myelodysplastic Syndrome

Data Insights

Ivonescimab by Akeso for Pancreatic Cancer: Likelihood of Approval

Ivonescimab is under clinical development by Akeso and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Ivonescimab in Pancreatic Cancer

Data Insights

Ivonescimab by Akeso for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval

Ivonescimab is under clinical development by Akeso and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Ivonescimab in Esophageal Squamous Cell Carcinoma (ESCC)

Data Insights

Ivonescimab by Akeso for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

Ivonescimab is under clinical development by Akeso and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Ivonescimab in Triple-Negative Breast Cancer (TNBC)

Data Insights

Ivonescimab by Akeso for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval

Ivonescimab is under clinical development by Akeso and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma....

Likelihood of Approval and Phase Transition Success Rate Model - Ivonescimab in Recurrent Head And Neck Squamous Cell Carcinoma

Data Insights

Ivonescimab by Akeso for Peritoneal Cancer: Likelihood of Approval

Ivonescimab is under clinical development by Akeso and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Ivonescimab in Peritoneal Cancer

Data Insights

Ivonescimab by Akeso for Fallopian Tube Cancer: Likelihood of Approval

Ivonescimab is under clinical development by Akeso and currently in Phase II for Fallopian Tube Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Ivonescimab in Fallopian Tube Cancer

Data Insights

Ivonescimab by Akeso for Gallbladder Cancer: Likelihood of Approval

Ivonescimab is under clinical development by Akeso and currently in Phase II for Gallbladder Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Ivonescimab in Gallbladder Cancer

Data Insights

Ivonescimab by Akeso for Gastric Cancer: Likelihood of Approval

Ivonescimab is under clinical development by Akeso and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Ivonescimab in Gastric Cancer

Data Insights

Ivonescimab by Akeso for Cervical Cancer: Likelihood of Approval

Ivonescimab is under clinical development by Akeso and currently in Phase II for Cervical Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Ivonescimab in Cervical Cancer

Data Insights

Ivonescimab by Akeso for Colorectal Cancer: Likelihood of Approval

Ivonescimab is under clinical development by Akeso and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Ivonescimab in Colorectal Cancer

Data Insights

Cadonilimab by Akeso for Colorectal Cancer: Likelihood of Approval

Cadonilimab is under clinical development by Akeso and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Cadonilimab in Colorectal Cancer

Data Insights

Ivonescimab by Akeso for Biliary Tract Disease: Likelihood of Approval

Ivonescimab is under clinical development by Akeso and currently in Phase II for Biliary Tract Disease. According to GlobalData, Phase...

Data Insights

Ligufalimab by Akeso for Non-Hodgkin Lymphoma: Likelihood of Approval

Ligufalimab is under clinical development by Akeso and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase I...

Data Insights

Ligufalimab by Akeso for Lymphoma: Likelihood of Approval

Ligufalimab is under clinical development by Akeso and currently in Phase I for Lymphoma. According to GlobalData, Phase I drugs...

Data Insights

Ligufalimab by Akeso for Solid Tumor: Likelihood of Approval

Ligufalimab is under clinical development by Akeso and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...

Data Insights

Dresbuxelimab by Akeso for Non-Small Cell Lung Cancer: Likelihood of Approval

Dresbuxelimab is under clinical development by Akeso and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Dresbuxelimab in Non-Small Cell Lung Cancer

Data Insights

Penpulimab by Akeso for Nasopharyngeal Cancer: Likelihood of Approval

Penpulimab is under clinical development by Akeso and currently in Pre-Registration for Nasopharyngeal Cancer. According to GlobalData, Pre-Registration drugs for...

Data Insights

Penpulimab by Akeso for Glioblastoma Multiforme (GBM): Likelihood of Approval

Penpulimab is under clinical development by Akeso and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData, Phase...

Data Insights

Manfidokimab by Akeso for Atopic Dermatitis (Atopic Eczema): Likelihood of Approval

Manfidokimab is under clinical development by Akeso and currently in Phase II for Atopic Dermatitis (Atopic Eczema). According to GlobalData,...